Research Blog

Our research blog documents the scientific peptide literature in a format aimed at study leads, pharmacologists, bioregulator researchers and independent researchers across Europe. We focus on four content axes: metabolic peptides (GLP-1/GIP/glucagon agonists like Retatrutide, targeted lipolysis tools like AOD-9604), regenerative peptides (BPC-157, TB-500, GHK-Cu plus the Wolverine and Glow stacks), longevity research (Khavinson bioregulators like Epitalon, mitochondrially encoded peptides like MOTS-c) and growth hormone secretagogues (Ipamorelin, CJC-1295, Tesamorelin).

Every article is written close to the primary sources. We consistently link to PubMed IDs, PMC full texts, FDA notices and peer-reviewed studies instead of citing research second-hand. Where the data is at Phase 2 or smaller, we say so clearly. Where studies were conducted in model systems (in vitro, animal models), we separate that from human data.

Practical research questions are answered with concrete protocols: reconstitution, storage, stability, dose ranges from the original literature, comparison of competing mechanisms of action. Every peptide in our catalogue ships with a third-party certificate of analysis from Janoshik Analytical for identity and purity, openly viewable batch by batch on the respective product page.

Current focus areas for 2026 are the Phase 3 data on Retatrutide (TRIUMPH programme), the EU situation after the Peptide Sciences shutdown of March 2026, the FDA warning letters on the 'Research Use Only' construct, and the growing literature on combined stack designs. Filter below by research focus or search all articles directly by compound.